Caleb Lee
Executive Director Daiichi Sankyo
Seminars
Tuesday 4th November 2025
Presentation Sneak Peek:
Evaluating the Breadth & Depth of I-DXd (Anti-B7-H3 ADC) Efficacy in Solid Tumors
- I-DXd is a B7-H3 directed ADC which has demonstrated efficacy in the Ph1 IDeate-PanTumor01 trial in SCLC and other solid tumors
- Interim results from the Ph2 IDeate-Lung01 trial dose optimization stage demonstrated ORR > 50% at the 12 mg/kg dose selected for expansion
- Primary analysis results from the IDeate-Lung01 trial in 2L+ SCLC will be presented
Tuesday 4th November 2025
Presentation Sneak Peek:
Evaluating the Breadth & Depth of I-DXd (Anti-B7-H3 ADC) Efficacy in Solid Tumors
- I-DXd is a B7-H3 directed ADC which has demonstrated efficacy in the Ph1 IDeate-PanTumor01 trial in SCLC and other solid tumors
- Interim results from the Ph2 IDeate-Lung01 trial dose optimization stage demonstrated ORR > 50% at the 12 mg/kg dose selected for expansion
- Primary analysis results from the IDeate-Lung01 trial in 2L+ SCLC will be presented
